HIV patients get safer flu shot options in new vaccine trial

NCT ID NCT01008813

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two versions of the H1N1 flu vaccine in 306 people living with HIV. One vaccine included an adjuvant (a booster ingredient) and the other did not. The goal was to see which vaccine was safer and better at protecting against the flu. Participants were followed for one year after receiving one or two shots.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CIC de Vaccinologie Cochin Pasteur, hôpital Cochin

    Paris, 75679, France

  • Hopital du Kremlin Bicêtre Service de médecine interne

    Kremlin Bicëtre, 94275, France

  • Hôpital Gustave Dron, Service Maladies Infectieuses

    Tourcoing, 59208, France

  • Hôpital Henri Mondor

    Créteil, 94010, France

  • Hôpital Saint-Louis

    Paris, 75010, France

  • Service des Maladies Infectieuses et Tropicales, Hopital Tenon

    Paris, 75020, France